ATE269865T1 - Pyrazolo(3,4-g)chinoxaline als pdgf-rezeptor protein tyrosin-kinase inhibitoren - Google Patents
Pyrazolo(3,4-g)chinoxaline als pdgf-rezeptor protein tyrosin-kinase inhibitorenInfo
- Publication number
- ATE269865T1 ATE269865T1 AT95932446T AT95932446T ATE269865T1 AT E269865 T1 ATE269865 T1 AT E269865T1 AT 95932446 T AT95932446 T AT 95932446T AT 95932446 T AT95932446 T AT 95932446T AT E269865 T1 ATE269865 T1 AT E269865T1
- Authority
- AT
- Austria
- Prior art keywords
- pyrazolo
- tyrosine kinase
- protein tyrosine
- quinoxaline
- pdgf receptor
- Prior art date
Links
- INGHAKCVSOYMIH-UHFFFAOYSA-N 4h-pyrazolo[4,3-g]quinoxaline Chemical compound C1=CN=C2CC3=CN=NC3=CC2=N1 INGHAKCVSOYMIH-UHFFFAOYSA-N 0.000 title abstract 3
- 108091008606 PDGF receptors Proteins 0.000 title abstract 3
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 title abstract 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000001747 exhibiting effect Effects 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940124606 potential therapeutic agent Drugs 0.000 abstract 1
- -1 pyrazolo[3,4-g]quinoxaline compound Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/303,097 US5476851A (en) | 1994-09-08 | 1994-09-08 | Pyrazolo[3,4-g]quinoxaline compounds which inhibit PDGF receptor protein tyrosine kinase |
| PCT/US1995/011414 WO1996007658A1 (en) | 1994-09-08 | 1995-09-06 | PYRAZOLO[3,4-g]QUINOXALINE COMPOUNDS WHICH INHIBIT PDGF RECEPTOR PROTEIN TYROSINE KINASE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE269865T1 true ATE269865T1 (de) | 2004-07-15 |
Family
ID=23170524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95932446T ATE269865T1 (de) | 1994-09-08 | 1995-09-06 | Pyrazolo(3,4-g)chinoxaline als pdgf-rezeptor protein tyrosin-kinase inhibitoren |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5476851A (de) |
| EP (1) | EP0779889B1 (de) |
| JP (1) | JP3952313B2 (de) |
| AT (1) | ATE269865T1 (de) |
| AU (1) | AU697518B2 (de) |
| CA (1) | CA2198005C (de) |
| DE (1) | DE69533194T2 (de) |
| ES (1) | ES2224134T3 (de) |
| MX (1) | MX9701820A (de) |
| WO (1) | WO1996007658A1 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999007701A1 (en) * | 1997-08-05 | 1999-02-18 | Sugen, Inc. | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors |
| EP1414500A4 (de) * | 2001-04-16 | 2005-01-12 | Uab Research Foundation | Akt und regulierung der synovialfibroblasten-apoptosis bei ra |
| DE60326950D1 (de) * | 2002-05-15 | 2009-05-14 | Janssen Pharmaceutica Nv | N-substituierte tricyclische 3-aminopyrazole als pdgf rezeptorenhemmer |
| US20040102360A1 (en) * | 2002-10-30 | 2004-05-27 | Barnett Stanley F. | Combination therapy |
| AU2004268614C1 (en) | 2003-08-27 | 2010-10-28 | Ophthotech Corporation | Combination therapy for the treatment of ocular neovascular disorders |
| AU2004291503A1 (en) * | 2003-11-13 | 2005-06-02 | Janssen Pharmaceutica N.V. | Immobilized N-substituted tricyclic 3-aminopyrazoles for the identification of biomolecular targets |
| EP1802608A1 (de) * | 2004-10-12 | 2007-07-04 | AstraZeneca AB | Chinazolinderivate zum einsatz gegen krebs |
| WO2006040522A1 (en) * | 2004-10-12 | 2006-04-20 | Astrazeneca Ab | Quinoline derivatives |
| US20060104951A1 (en) * | 2004-11-16 | 2006-05-18 | Mountz John D | Akt and regulation of RA synovial fibroblast apoptosis |
| EP2400985A2 (de) | 2009-02-25 | 2012-01-04 | OSI Pharmaceuticals, LLC | Kombination eines anti-igf-1r-antikörpers oder eines igf-bindungsproteins und eines kleinmoleküligen igf-1r-kinase-inhibitors |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| EP2401614A1 (de) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Verfahren zur identifizierung von mesenchymähnlichen tumorzellen oder deren bildung hemmenden stoffen |
| JP2012519282A (ja) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法 |
| US9896730B2 (en) | 2011-04-25 | 2018-02-20 | OSI Pharmaceuticals, LLC | Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| CN112020357B (zh) * | 2019-04-02 | 2023-08-29 | 上海翰森生物医药科技有限公司 | 含吲唑基的三并环类衍生物的盐及其晶型 |
| EP4126833A1 (de) * | 2020-03-23 | 2023-02-08 | Helmholtz-Zentrum für Infektionsforschung GmbH | N-phenyl-3-mercaptopropanamidderivate als metallo-beta-lactamase-hemmer zur behandlung von bakteriellen infektionen |
| WO2025236095A1 (en) * | 2024-05-17 | 2025-11-20 | Congruence Therapeutics Inc. | Modulators of alpha-1 antitrypsin |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3701277A1 (de) * | 1987-01-17 | 1988-07-28 | Boehringer Mannheim Gmbh | Neue tricyclische benzimidazole, verfahren zu ihrer herstellung und verwendung als arzneimittel |
| DK160941C (da) * | 1988-06-28 | 1991-10-21 | Novo Nordisk As | Kondenserede 2,3-dihydroxypyraziner, fremgangsmaade til deres fremstilling og farmaceutiske praeparater, hvori forbindelserne indgaar |
| AU658646B2 (en) * | 1991-05-10 | 1995-04-27 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| GB9314884D0 (en) * | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Tricyclic derivatives |
| IL112248A0 (en) * | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
-
1994
- 1994-09-08 US US08/303,097 patent/US5476851A/en not_active Expired - Lifetime
-
1995
- 1995-09-06 AT AT95932446T patent/ATE269865T1/de not_active IP Right Cessation
- 1995-09-06 DE DE69533194T patent/DE69533194T2/de not_active Expired - Lifetime
- 1995-09-06 ES ES95932446T patent/ES2224134T3/es not_active Expired - Lifetime
- 1995-09-06 WO PCT/US1995/011414 patent/WO1996007658A1/en not_active Ceased
- 1995-09-06 MX MX9701820A patent/MX9701820A/es unknown
- 1995-09-06 CA CA002198005A patent/CA2198005C/en not_active Expired - Fee Related
- 1995-09-06 EP EP95932446A patent/EP0779889B1/de not_active Expired - Lifetime
- 1995-09-06 JP JP50968896A patent/JP3952313B2/ja not_active Expired - Fee Related
- 1995-09-06 AU AU35491/95A patent/AU697518B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| MX9701820A (es) | 1997-06-28 |
| EP0779889A1 (de) | 1997-06-25 |
| ES2224134T3 (es) | 2005-03-01 |
| CA2198005A1 (en) | 1996-03-14 |
| WO1996007658A1 (en) | 1996-03-14 |
| DE69533194T2 (de) | 2005-08-11 |
| CA2198005C (en) | 2007-06-12 |
| DE69533194D1 (de) | 2004-07-29 |
| JPH10505093A (ja) | 1998-05-19 |
| JP3952313B2 (ja) | 2007-08-01 |
| EP0779889A4 (de) | 2000-02-23 |
| AU3549195A (en) | 1996-03-27 |
| US5476851A (en) | 1995-12-19 |
| AU697518B2 (en) | 1998-10-08 |
| EP0779889B1 (de) | 2004-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE269865T1 (de) | Pyrazolo(3,4-g)chinoxaline als pdgf-rezeptor protein tyrosin-kinase inhibitoren | |
| ATE202076T1 (de) | Ester der 5-aminolevulinsäure als mittel zur photosensibilisierung in der chemotherapie | |
| DK0668863T3 (da) | Quinuclidinderivat som substans P-antagonist | |
| DE60316779D1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| LV12291A (lv) | Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai | |
| DE69736441D1 (de) | Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen | |
| DE60126980D1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| BR9917038A (pt) | Composto, composição farmacêutica, método de modulação da atividade receptora de quimocinas, método de tratamento ou prevenção de doenças inflamatórias, método de tratamento ou prevenção de asma e método de tratamento ou prevenção de disfunções inflamatórias | |
| EA200400283A1 (ru) | Производные аминофталазинона, активные как ингибиторы киназ, способ их получения и содержащие их фармацевтические композиции | |
| ATE269846T1 (de) | N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen | |
| BR9507073A (pt) | Composto processos para preparar o mesmo e para tratar uma doença no sistema nervoso central composiçao farmacêutica e uso do composto | |
| DE60024857D1 (de) | Neue verbindungen | |
| IL136733A0 (en) | Pharmaceutical composition containing sibutramine and orlistat | |
| PL350891A1 (en) | Substituted 1,4-dichlorindene[1,2-c]pyrazoles as inhibitors of tyrosine kinase | |
| DK0823909T3 (da) | Hidtil ukendte heterocykliske forbindelser | |
| KR970703152A (ko) | 치료제 용도의 피리딜비스인산염(pyridylbisphosphonates for use as a therapeutical agent) | |
| GR3032950T3 (en) | Substituted fused and bridged bicyclic compounds as therapeutic agents | |
| CA2301590A1 (en) | 2-aminopyridines as inhibitors of cyclooxygenase-2 | |
| NZ504124A (en) | Phenyl-alkyl-imidazoles and use in treating inflammatory disease | |
| PT1025101E (pt) | Derivados de nafto-imidazo¬1,2-a|piridina sua preparacao e uso no tratamento de perturbacoes do sistema nervoso central | |
| RU99118510A (ru) | Композиция для лечения или предупреждения рака простаты | |
| LV12459A (lv) | Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai | |
| RU94035756A (ru) | Производные имидазола, являющиеся ингибиторами питокинов, способы их получения, фармацевтическая композиция |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |